Vertex Pharmaceuticals (VRTX) Change in Receivables (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Change in Receivables of -$39.8 million for Q1 2026, down 123.47% year-over-year from $169.6 million in Q1 2025, and down 140.04% quarter-over-quarter from $99.4 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Change in Receivables (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Change in Receivables history runs 18 years deep, the most recent figure standing at -$39.8 million for Q1 2026.
- In Q1 2026, Change in Receivables fell 123.47% year-over-year to -$39.8 million; the TTM figure through Mar 2026 stood at $137.9 million (up 697.11% YoY), while the FY2025 annual figure was $347.3 million, up 249.75% from the prior year.
- Change in Receivables for Q1 2026 stood at -$39.8 million, down from $99.4 million in the prior quarter.
- The five-year high for Change in Receivables was $251.6 million in Q1 2024, with the low at -$135.1 million in Q2 2024.
- The 5-year median for Change in Receivables is $51.8 million (2024), against an average of $50.0 million.
- Peak annual rise in Change in Receivables reached 749.18% in 2024, while the deepest fall reached 4758.62% in 2024.
- Vertex Pharmaceuticals' Change in Receivables stood at -$10.2 million in 2022, then sank by 50.98% to -$15.4 million in 2023, then sank by 348.05% to -$69.0 million in 2024, then surged by 244.06% to $99.4 million in 2025, then tumbled by 140.04% to -$39.8 million in 2026.
- Business Quant data shows VRTX's Change in Receivables at -$39.8 million in Q1 2026, $99.4 million in Q4 2025, and $59.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 140.20 Mn |
| Jun 30, 2026 | 140.20 Mn |
| Mar 31, 2026 | -39.80 Mn |
| Mar 31, 2026 | -39.80 Mn |
| Dec 31, 2025 | 99.40 Mn |
| Dec 31, 2025 | 99.40 Mn |
| Sep 30, 2025 | 59.90 Mn |
| Sep 30, 2025 | 59.90 Mn |
| Jun 30, 2025 | 18.40 Mn |
| Jun 30, 2025 | 18.40 Mn |
| Mar 31, 2025 | 169.60 Mn |
| Mar 31, 2025 | 169.60 Mn |
| Dec 31, 2024 | -69.00 Mn |
| Dec 31, 2024 | -69.00 Mn |
| Sep 30, 2024 | 51.80 Mn |
| Sep 30, 2024 | 51.80 Mn |
| Jun 30, 2024 | -135.10 Mn |
| Jun 30, 2024 | -135.10 Mn |
| Mar 31, 2024 | 251.60 Mn |
| Mar 31, 2024 | 251.60 Mn |